![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Press Releases
Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma
Nycomed announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd....
Press Releases
PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia
PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2...
Press Releases
Celator Pharmaceuticals completes enrollment in a second phase 2 trail of CPX-351in acute myeloid leukemia
Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive...
Press Releases
Eurand Presents Data on ZENPEP(R) Without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients With CF and Pancreatic Insufficiency
Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. announced additional data from a post-hoc analysis of a Phase III clinical...
Press Releases
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL(R) (armodafinil) Tablets and PROVIGIL(R) (modafinil) Tablets...
Press Releases
FDA approves Herceptin for HER2-positive metastatic stomach cancer
Roche announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil )...
Press Releases
Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON(TM)
Amylin Pharmaceuticals, Inc. Eli Lilly and Company and Alkermes, Inc.announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read